Elevate Prize Foundation Launches Application for $5M Elevate Prize
10.3.2021 17:00:00 EET | Business Wire | Press release
The Elevate Prize Foundation is pleased to announce the launch of its second year of the Elevate Prize, which will commit $5 million in funding and services to 10 prize winners. The Foundation is searching for social impact leaders globally who are tackling the most pressing challenges of our time, with the most innovative and effective solutions.
Founders and CEOs of nonprofits and public charities worldwide are welcome to apply to win one of 10 annual Elevate Prizes. New this year is a simplified, two-phase application, making it significantly easier for nonprofit leaders to apply for the Prize. Phase 1, now open to all applicants, includes a shortened written application, while Phase 2 will include a more robust set of questions, released only to select applicants this summer.
The Elevate Prize Foundation, founded in 2019 by entrepreneur and philanthropist Joseph Deitch, is dedicated to giving unsung social entrepreneurs the necessary resources to scale their impact, and to ultimately help inspire and awaken the hero in all of us. The Foundation awarded its inaugural class of 10 winners in October 2020.
Each winner of this year’s Elevate Prize will receive:
- MONEY. A minimum of $300,000 (USD) shared between winners and their nonprofit organizations, so they can collectively drive change.
- AMPLIFICATION. Our strategic marketing and media expertise can take winners to the next level. Be a social impact influencer. Find fans. Build a platform. Think bigger. Do great things. Change the world.
- MENTORSHIP. Our network of partners, executives and decision-makers offer the kind of professional development and business guidance money can’t buy.
- CONNECTIONS. Each cohort is a radically diverse group of people leading innovative organizations. As a member of this cohort, winners will have the opportunity to learn from each other, create shared experiences, and build lasting relationships.
- SUPPORT. We take the time to thoroughly understand winners’ needs as an individual and organization, and then create a tailored program that will help each winner reach their goals and beyond.
“The Elevate Prize remains committed to finding a radically diverse group of innovative problem solvers, and investing unconventional and personalized resources that bring greater visibility to them as leaders and the vital work they do. We make good famous,” said Carolina García Jayaram, executive director, Elevate Prize Foundation.
The Foundation is proud to partner with MIT Solve on this year’s Elevate Prize. As an extension of its partnership, the Foundation will commit one of its 10 Prizes to MIT Solve’s first US Challenge on Antiracist Technology. The Elevate Prize for Antiracist Technology is open to nonprofit leaders who are helping to create an antiracist and equitable future in the U.S. This exemplar leader will take part in both the MIT Solver program and the Elevate Prize program and receive ongoing support from both organizations.
The application process for the Prize begins today at www.elevateprize.org/apply and applicants can submit up until the May 5 deadline. Following this deadline, select applicants will be invited to complete Phase 2 of the application. Winners will be announced in October 2021.
About the Elevate Prize Foundation
Founded in 2019 by businessman, philanthropist, and author Joseph Deitch, the Elevate Prize Foundation aims to elevate humanity on a global scale by funding, guiding, and scaling the platforms of social entrepreneurs. The Foundation’s signature program is its annual Elevate Prize – a search for innovators and activists that culminates with the selection of 10 leaders to receive funding and guidance to amplify their work. These changemakers are working to solve the world’s problems within healthcare, the environment, poverty, inequality, the arts, and more. Elevate Prize winners embark on a two-year program fueled by access to top scholars and industry leaders who guide and support them in scaling their impact. Together, Prize winners, advisors, partners, and collaborators across industries combine their impressive reach to create a single, powerful philanthropic amplification platform to awaken the hero in all of us. For more information, visit www.elevateprize.org and follow @ElevatePrize on Facebook, Instagram, LinkedIn, and Twitter.
About MIT Solve
Solve is an initiative of the Massachusetts Institute of Technology (MIT) with a mission to solve world challenges. Solve is a marketplace for social impact innovation. Through open innovation Challenges, Solve finds incredible tech-based social entrepreneurs all around the world. Solve then brings together MIT’s innovation ecosystem and a community of Members to fund and support these entrepreneurs to help them drive lasting, transformational impact. Join Solve on this journey at solve.mit.edu.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005111/en/
Contact information
CashmanCo
Lily Freedberg
lily@cashmanco.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
